Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: Perspectives on Hepatitis C Care in the US and Australia—Audio Recap

Listen to insights from 2 expert faculty in this dialogue on lessons learned in the care of patients with HCV infection during the COVID-19 pandemic, including patients who inject drugs.
Gregory Dore, MBBS, PhD, FRACP, MPH
Stacey Trooskin, MD, PhD, MPH
Released: November 10, 2021

In this episode, Gregory Dore, MBBS, PhD, FRACP, MPH, and Stacey Trooskin, MD, PhD, MPH, share lessons learned in the care of patients with HCV infection during the COVID-19 pandemic, including:

  • Telehealth
  • Treatment of PWID
  • TEMPO pilot study
  • MINMON study

Information on this Educational Activity

Faculty

Gregory Dore, MBBS, PhD, FRACP, MPH

Professor, Head
Viral Hepatitis Clinical Research Program
Kirby Institute
University of New South Wales
Professor
Infectious Diseases Physician
St Vincent's Hospital
Sydney, Australia

Greg Dore, MBBS, PhD, FRACP, MPH, has no relevant conflicts of interest to report.
Stacey Trooskin, MD, PhD, MPH

Chief Medical Officer
Philadelphia FIGHT Community Health Centers
Faculty
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Stacey Trooskin, MD, PhD, MPH, has disclosed that she has received funds for research support and consulting fees from Gilead Sciences.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings